 Michael Taravella
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phacoemulsification | 8 | 2022 | 123 | 2.960 |
Why?
| | Cataract Extraction | 10 | 2024 | 120 | 1.580 |
Why?
| | Cataract | 5 | 2024 | 212 | 1.560 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 3 | 2022 | 6 | 1.520 |
Why?
| | Lens Implantation, Intraocular | 7 | 2021 | 80 | 1.490 |
Why?
| | Intraoperative Complications | 3 | 2020 | 157 | 1.310 |
Why?
| | Visual Acuity | 7 | 2020 | 491 | 1.180 |
Why?
| | Endothelium, Corneal | 3 | 2022 | 18 | 1.170 |
Why?
| | Keratomileusis, Laser In Situ | 4 | 2020 | 20 | 1.110 |
Why?
| | Myopia | 4 | 2021 | 59 | 0.950 |
Why?
| | Tissue and Organ Harvesting | 3 | 2022 | 78 | 0.910 |
Why?
| | Corneal Diseases | 6 | 2013 | 46 | 0.890 |
Why?
| | Lenses, Intraocular | 4 | 2021 | 49 | 0.850 |
Why?
| | Cornea | 8 | 2021 | 154 | 0.720 |
Why?
| | Lasers, Excimer | 4 | 2020 | 30 | 0.720 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.650 |
Why?
| | Refraction, Ocular | 2 | 2021 | 47 | 0.650 |
Why?
| | Lens Capsule, Crystalline | 1 | 2020 | 10 | 0.640 |
Why?
| | Retinal Diseases | 1 | 2020 | 101 | 0.590 |
Why?
| | Angiogenesis Inhibitors | 1 | 2020 | 238 | 0.560 |
Why?
| | Eye Banks | 2 | 2020 | 7 | 0.550 |
Why?
| | Education, Medical, Graduate | 2 | 2014 | 562 | 0.520 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.500 |
Why?
| | Tissue Donors | 2 | 2022 | 413 | 0.450 |
Why?
| | Photorefractive Keratectomy | 3 | 2001 | 21 | 0.440 |
Why?
| | Laser Therapy | 1 | 2016 | 140 | 0.420 |
Why?
| | Surgical Flaps | 4 | 2016 | 142 | 0.390 |
Why?
| | Microtomy | 1 | 2013 | 4 | 0.380 |
Why?
| | Descemet Membrane | 3 | 2022 | 7 | 0.380 |
Why?
| | Scleritis | 3 | 2022 | 28 | 0.370 |
Why?
| | Sulfonamides | 1 | 2016 | 579 | 0.370 |
Why?
| | Intraocular Pressure | 4 | 2024 | 326 | 0.360 |
Why?
| | Internship and Residency | 2 | 2014 | 1262 | 0.350 |
Why?
| | Teaching | 1 | 2014 | 237 | 0.340 |
Why?
| | Learning Curve | 1 | 2011 | 70 | 0.330 |
Why?
| | Capsule Opacification | 1 | 2010 | 18 | 0.320 |
Why?
| | Lasers, Solid-State | 1 | 2010 | 22 | 0.320 |
Why?
| | Ophthalmology | 1 | 2011 | 116 | 0.300 |
Why?
| | Postoperative Complications | 6 | 2013 | 2950 | 0.290 |
Why?
| | Aqueous Humor | 4 | 2001 | 38 | 0.280 |
Why?
| | Cell Count | 3 | 2022 | 320 | 0.280 |
Why?
| | Collagen | 3 | 1999 | 450 | 0.260 |
Why?
| | Retrospective Studies | 11 | 2021 | 17149 | 0.260 |
Why?
| | Clinical Competence | 2 | 2014 | 1237 | 0.250 |
Why?
| | Humans | 38 | 2024 | 144667 | 0.240 |
Why?
| | Follow-Up Studies | 6 | 2020 | 5414 | 0.220 |
Why?
| | Drug Delivery Systems | 2 | 1999 | 380 | 0.220 |
Why?
| | Corneal Stroma | 2 | 2001 | 24 | 0.210 |
Why?
| | Prosthesis Design | 2 | 2020 | 355 | 0.200 |
Why?
| | Conjunctiva | 2 | 2007 | 52 | 0.200 |
Why?
| | Male | 18 | 2020 | 72431 | 0.180 |
Why?
| | Iris | 1 | 2001 | 23 | 0.180 |
Why?
| | Aged | 10 | 2020 | 25955 | 0.180 |
Why?
| | Microscopy | 2 | 2022 | 148 | 0.180 |
Why?
| | Cyanoacrylates | 1 | 2001 | 3 | 0.170 |
Why?
| | Hyperopia | 1 | 2001 | 19 | 0.170 |
Why?
| | Tissue Adhesives | 1 | 2001 | 22 | 0.170 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 7 | 0.170 |
Why?
| | Calcinosis | 2 | 1994 | 234 | 0.160 |
Why?
| | Air Pollutants, Occupational | 1 | 2001 | 41 | 0.160 |
Why?
| | Corneal Transplantation | 1 | 2020 | 17 | 0.160 |
Why?
| | Rupture | 1 | 2020 | 91 | 0.160 |
Why?
| | Intravitreal Injections | 1 | 2020 | 71 | 0.160 |
Why?
| | Keratoconus | 1 | 2020 | 23 | 0.150 |
Why?
| | Ectodermal Dysplasia | 1 | 1999 | 19 | 0.150 |
Why?
| | Diabetic Retinopathy | 1 | 2022 | 199 | 0.150 |
Why?
| | Ofloxacin | 1 | 1999 | 17 | 0.150 |
Why?
| | Poliovirus | 1 | 1999 | 73 | 0.140 |
Why?
| | Homosexuality, Male | 1 | 2020 | 223 | 0.140 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.140 |
Why?
| | Colorado | 3 | 2024 | 4558 | 0.140 |
Why?
| | Eye Injuries, Penetrating | 1 | 1998 | 19 | 0.140 |
Why?
| | Snake Bites | 1 | 1998 | 24 | 0.140 |
Why?
| | Tobramycin | 1 | 1998 | 59 | 0.140 |
Why?
| | Eyelids | 1 | 1998 | 41 | 0.140 |
Why?
| | Pseudallescheria | 1 | 1997 | 3 | 0.130 |
Why?
| | Corneal Injuries | 1 | 1998 | 42 | 0.130 |
Why?
| | Boidae | 1 | 1998 | 31 | 0.130 |
Why?
| | Mycetoma | 1 | 1997 | 6 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 550 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 638 | 0.130 |
Why?
| | Female | 12 | 2020 | 78304 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2020 | 8284 | 0.130 |
Why?
| | Anterior Capsule of the Lens | 1 | 2016 | 2 | 0.120 |
Why?
| | Capsulorhexis | 1 | 2016 | 8 | 0.120 |
Why?
| | Prevalence | 1 | 2024 | 2839 | 0.120 |
Why?
| | Anti-Infective Agents | 1 | 1999 | 242 | 0.120 |
Why?
| | Dexamethasone | 2 | 1998 | 366 | 0.120 |
Why?
| | Lung | 2 | 1999 | 4089 | 0.110 |
Why?
| | Prednisolone | 1 | 1994 | 66 | 0.100 |
Why?
| | Models, Biological | 1 | 2001 | 1811 | 0.100 |
Why?
| | Herpesvirus 3, Human | 1 | 1997 | 337 | 0.100 |
Why?
| | Safety | 3 | 2001 | 356 | 0.100 |
Why?
| | Down Syndrome | 1 | 2020 | 522 | 0.100 |
Why?
| | Operative Time | 1 | 2014 | 181 | 0.100 |
Why?
| | Hospital Costs | 1 | 2014 | 125 | 0.100 |
Why?
| | Ophthalmic Solutions | 3 | 1999 | 79 | 0.090 |
Why?
| | Staining and Labeling | 1 | 2013 | 153 | 0.090 |
Why?
| | Operating Rooms | 1 | 2014 | 143 | 0.090 |
Why?
| | Middle Aged | 8 | 2020 | 35971 | 0.090 |
Why?
| | Hospitals, Teaching | 1 | 2011 | 119 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 1998 | 1928 | 0.080 |
Why?
| | Corneal Topography | 2 | 2020 | 25 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 1994 | 477 | 0.080 |
Why?
| | Incidence | 2 | 2010 | 2892 | 0.080 |
Why?
| | Methacrylates | 1 | 2010 | 119 | 0.080 |
Why?
| | Cell Survival | 1 | 2013 | 1092 | 0.080 |
Why?
| | Risk Factors | 1 | 2024 | 10796 | 0.070 |
Why?
| | Virus Cultivation | 2 | 1999 | 31 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2573 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2016 | 3603 | 0.060 |
Why?
| | Adult | 6 | 2020 | 40489 | 0.060 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2006 | 31 | 0.060 |
Why?
| | Polymers | 1 | 2010 | 492 | 0.060 |
Why?
| | Administration, Topical | 2 | 1998 | 152 | 0.060 |
Why?
| | United States | 2 | 2020 | 16018 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 1998 | 1044 | 0.060 |
Why?
| | Surgical Wound Infection | 2 | 1999 | 330 | 0.050 |
Why?
| | Tonometry, Ocular | 1 | 2024 | 103 | 0.050 |
Why?
| | Fibroblasts | 2 | 1999 | 1019 | 0.050 |
Why?
| | Polypropylenes | 1 | 2022 | 12 | 0.050 |
Why?
| | Time Factors | 1 | 2014 | 7140 | 0.050 |
Why?
| | Sutures | 1 | 2022 | 65 | 0.040 |
Why?
| | Mechanics | 1 | 2001 | 2 | 0.040 |
Why?
| | Miosis | 1 | 2001 | 4 | 0.040 |
Why?
| | Iris Diseases | 1 | 2001 | 7 | 0.040 |
Why?
| | Glucocorticoids | 2 | 1998 | 528 | 0.040 |
Why?
| | Blinking | 1 | 2001 | 11 | 0.040 |
Why?
| | Finite Element Analysis | 1 | 2001 | 67 | 0.040 |
Why?
| | Rheology | 1 | 2001 | 94 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 2001 | 15 | 0.040 |
Why?
| | Environmental Pollution | 1 | 2001 | 20 | 0.040 |
Why?
| | Volatilization | 1 | 2001 | 53 | 0.040 |
Why?
| | Anterior Chamber | 1 | 2001 | 26 | 0.040 |
Why?
| | Aberrometry | 1 | 2021 | 9 | 0.040 |
Why?
| | Optics and Photonics | 1 | 2021 | 39 | 0.040 |
Why?
| | Biometry | 1 | 2021 | 66 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2020 | 16 | 0.040 |
Why?
| | Respiration | 1 | 2001 | 206 | 0.040 |
Why?
| | Adolescent | 3 | 2020 | 22409 | 0.040 |
Why?
| | Nuclear Family | 1 | 1999 | 50 | 0.040 |
Why?
| | Smoke | 1 | 2001 | 147 | 0.040 |
Why?
| | Particle Size | 1 | 2001 | 401 | 0.040 |
Why?
| | Canada | 1 | 2020 | 432 | 0.040 |
Why?
| | Young Adult | 2 | 2020 | 14122 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 1999 | 232 | 0.040 |
Why?
| | Biological Dressings | 1 | 1998 | 2 | 0.030 |
Why?
| | Trifluridine | 1 | 1998 | 3 | 0.030 |
Why?
| | Reoperation | 1 | 2001 | 624 | 0.030 |
Why?
| | Pterygium | 1 | 1997 | 4 | 0.030 |
Why?
| | Eye Enucleation | 1 | 1997 | 14 | 0.030 |
Why?
| | Sclera | 1 | 1997 | 36 | 0.030 |
Why?
| | Computer Simulation | 1 | 2001 | 1021 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1999 | 580 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 1998 | 373 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2007 | 2922 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2020 | 557 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2001 | 607 | 0.030 |
Why?
| | Prospective Studies | 2 | 1999 | 7994 | 0.030 |
Why?
| | Cytomegalovirus Retinitis | 1 | 1996 | 22 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1501 | 0.030 |
Why?
| | DNA, Viral | 1 | 1997 | 357 | 0.030 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 130 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 1997 | 1047 | 0.030 |
Why?
| | Ultrasonography | 1 | 1997 | 776 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 1997 | 834 | 0.020 |
Why?
| | Antiviral Agents | 1 | 1998 | 765 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1999 | 4110 | 0.020 |
Why?
| | Ultrasonic Therapy | 1 | 1991 | 16 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3414 | 0.020 |
Why?
| | Infant, Newborn | 1 | 1999 | 6399 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6041 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2754 | 0.020 |
Why?
| | Arteritis | 1 | 2006 | 23 | 0.020 |
Why?
| | Suture Techniques | 1 | 2007 | 137 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2001 | 11735 | 0.010 |
Why?
| | Infant | 1 | 1999 | 10023 | 0.010 |
Why?
| | Child, Preschool | 1 | 2020 | 11790 | 0.010 |
Why?
| | Child | 1 | 2020 | 22600 | 0.010 |
Why?
| | Animals | 2 | 1998 | 37948 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1998 | 169 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2007 | 1170 | 0.010 |
Why?
| | Drug Carriers | 1 | 1998 | 132 | 0.010 |
Why?
| | Swine | 1 | 1998 | 828 | 0.010 |
Why?
| | Macrophages | 1 | 1996 | 1496 | 0.000 |
Why?
|
|
Taravella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|